MissionIR Articles
Original content written and distributed as part of our ongoing relationships.
-
VistaGen Therapeutics (VSTA) Announces Positive AV-101 Preclinical Data Suggesting Potential for Parkinson’s Disease
VistaGen Therapeutics, Inc., a biopharmaceutical company developing drugs for treating neurological disorders and diabetes, announced today positive preclinical data supporting expanded applications of AV-101, the Company’s first in-class prodrug that regulates critical NMDA receptors in…
-
VistaGen Therapeutics (VSTA) and Sanwa Renew Embryonic Stem Cell Drug Discovery and Development Partnership Focused on New Diabetes Treatments
VistaGen Therapeutics, Inc., a biopharmaceutical company pioneering the use of embryonic stem cells as proprietary biological systems for discovery and development of novel drugs for the treatment of diabetes and central nervous system disorders, announced…
-
VistaGen Therapeutics (VSTA) and CATO BioVentures Sign Strategic Business Development Agreement for CNS Products
VistaGen Therapeutics Inc., a biopharmaceutical company applying leading embryonic stem cell technology to discover and develop novel treatments for central nervous system disorders, diabetes and cardiovascular disease, and Cato BioVentures, the venture capital affiliate of…
-
Lantos Affirms Support of Expanded Stem Cell Research — Applauds Commitment by VistaGen Employees and Investors
Congressman Tom Lantos (D-San Francisco, San Mateo) speaking from the laboratories of VistaGen Therapeutics, a biopharmaceutical company, affirmed his support of the expansion of stem cell research using human embryos that would otherwise become medical…
-
VistaGen Therapeutics Secures Development Support for New Drug Candidate forHuntington’s Disease
VistaGen Therapeutics, Inc., a development stage biopharmaceutical company focused on discovering, developing and commercializing novel small molecule and protein therapeutics using embryonic stem cell technologies, announced today that the High Q Foundation, Inc. has agreed…
-
VistaGen Therapeutics (VSTA) Awarded $197,000 NIH Grant for Expanded PreclinicalDevelopment of New Drug Candidate for Neuropathic Pain
VistaGen Therapeutics, Inc., a development stage biopharmaceutical company focused on discovering, developing and commercializing novel small molecule and protein therapeutics for Central Nervous System (CNS) and Peripheral Nervous System (PNS) disorders and metabolic diseases using…
-
VistaGen Therapeutics (VSTA) Awarded $3,700,000 NIH Drug Development Grant for LeadEpilepsy Drug Candidate
Burlingame, CA, May 24, 2005 /PRNewswire/ — VistaGen Therapeutics, Inc., a development stage biopharmaceutical company focused on discovering, developing and commercializing novel small molecule and protein therapeutics for Central Nervous System (CNS) disorders and metabolic…
Search Articles
Latest Articles
- MissionIRNewsBreaks – AI-Driven Energy Demands Highlight Strategic Value of Platinum Group Metals Ltd.’s (NYSE American: PLG) (TSX: PTM) Waterberg Project
- Brera Holdings PLC’s (NASDAQ: BREA) Becomes Second Multi-Club Owner in Italy’s Serie B, Signaling Rising Investment Opportunity
- MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics(TM) Secures Florida Regulatory Clearance to Close Dura Medical Acquisition
- MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures FDA Type C Meeting for AVERSA(TM) Fentanyl Abuse-Deterrent Patch
- MissionIRNewsBreaks – Silvercorp Metals Inc. (TSX: SVM) (NYSE American: SVM) Reports Q1 Fiscal 2026 Net Income of $18.1 Million on $81.3 Million Revenue